Literature DB >> 11106246

High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

M N Holten-Andersen1, R W Stephens, H J Nielsen, G Murphy, I J Christensen, W Stetler-Stevenson, N Brünner.   

Abstract

The objective of the present study was to measure preoperative plasma tissue inhibitor of metalloproteinase (TIMP)-1 levels in colorectal cancer patients and relate these values to clinical and biochemical patient characteristics. TIMP-1 levels were determined by ELISA in EDTA plasma samples collected preoperatively from 588 colorectal cancer patients. Plasma TIMP-1 levels were distributed with a median value of 141.1 microg/liter (range, 53.7-788.7 microg/liter). Whereas no significant differences were found in the median plasma TIMP-1 levels among patients with Dukes' stage A, B, and C disease, patients with Dukes' stage D disease had significantly higher plasma TIMP-1 levels (P < 0.0001); however, high plasma TIMP-1 levels were not restricted to advanced disease. A relatively weak correlation between plasma TIMP-1 level and age was found (r = 0.35; P < 0.0001). There was no significant difference in TIMP-1 levels between males and females (P = 0.97). Univariate analysis demonstrated an increasing risk of mortality with increasing TIMP-1 levels [scored as the log(e)(TIMP-1); hazard ratio = 3.3; 95% confidence interval, 2.6-4.2; P < 0.0001]. Including covariates (Dukes' stage, primary tumor location, gender, age, plasminogen activator inhibitor type 1, and soluble urokinase plasminogen activator receptor) in a multivariate analysis, TIMP-1 was retained in the final model (hazard ratio = 2.5; 95% confidence interval, 1.7-3.7; P < 0.0001). This study showed a highly significant association between preoperative plasma TIMP-1 levels and survival in colorectal cancer patients, with higher plasma TIMP-1 levels being associated with poor outcome. Independent of clinical parameters including Dukes' stage, plasma TIMP-1 levels were found to strongly predict prognosis of colorectal cancer patients. Additional studies are needed to validate the clinical usefulness of plasma TIMP-1 measurements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106246

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

3.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

4.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

5.  Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy.

Authors:  B Hanke; A Wein; P Martus; C Riedel; M Voelker; E G Hahn; D Schuppan
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients.

Authors:  Kuvaja Paula; Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Journal:  Biomark Insights       Date:  2007-04-03

7.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

Review 8.  Biomarkers for colorectal cancer.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka; Rikako Ishigamori
Journal:  Int J Mol Sci       Date:  2010-09-13       Impact factor: 5.923

Review 9.  Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Authors:  Kim Y C Fung; Edouard Nice; Ilka Priebe; Damien Belobrajdic; Aloke Phatak; Leanne Purins; Bruce Tabor; Celine Pompeia; Trevor Lockett; Timothy E Adams; Antony Burgess; Leah Cosgrove
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles.

Authors:  Hanne Offenberg; Nils Brünner; Francisco Mansilla; F Orntoft Torben; Karin Birkenkamp-Demtroder
Journal:  Mol Oncol       Date:  2008-06-18       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.